Breaking News

Crucell, Novartis Sign Licensing Deal

Crucell N.V. and Novartis Vaccines and Diagnostics, Inc. have extended a non-exclusive research license agreement for PER.C6. The agreement allows Novartis to use Crucell’s cell technology in manufacturing alphavirus vectors for its vaccine research programs. Financial details were not disclosed.

The PER.C6 technology is a cell line for the development and large-scale manufacture of biopharma products including vaccines.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters